Skip to main content
. 2016 Nov 4;7(50):83071–83087. doi: 10.18632/oncotarget.13068

Figure 1. Crambescidins decrease viability of a wide range of tumor cells.

Figure 1

A. Chemical structures of crambescidin 816, crambescidin 830 and crambescidin 800. B. Viability of HOP-92, OVCAR-3, HT-29, SK-MEL-2, OU-31 and MCF-7 cells after C830 and C800 treatments for 24 and 48 h, determined by the MTT method. *Significant difference with respect to controls (p <0.01). C. Dose-dependent decrease of cell viability in response to C816, C830 and C800 determined by the alamarBlue® assay. HepG2 cells were treated with different concentrations of C816, C830 and C800 ranging from 0.1 to 15 μM for 48 h to determine the IC50 dose. D. Dose-dependent decrease of HepG2 cells viability in response to 0.1-15 μM C816, C830 and C800 and IC50 determination at 72 h.